CompletedPhase 2NCT01122784

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

Studying Plague

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: DynPort Vaccine Company LLC, A GDIT Company
Principal Investigator: George Saviolakis, MD
DynPort Vaccine Company, a CSC Company
Intervention: rF1V vaccine (with Adjuvant)(biological)
Enrollment: 402 target
Eligibility: 18-55 years · All sexes
Timeline: 2010 – 2012

Study locations (11)

Benchmark Research, San Francisco, California, United States
Apex Research Institute, Santa Ana, California, United States
Johnson County Clinical Trials, Lenexa, Kansas, United States
Heartland Reseach Assoicates, LLC, Wichita, Kansas, United States
Central Kentucky Research Associates, Lexington, Kentucky, United States
WRAIR Clinical Trials Center, Silver Spring, Maryland, United States
Center for Pharmceutical Research, Kansas City, Missouri, United States
Rochester Clinical Research, Rochester, New York, United States
Wake Research Associates, Raleigh, North Carolina, United States
Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01122784 on ClinicalTrials.gov

Other trials for Plague

Additional recruiting or active studies for the same condition.

See all trials for Plague →

← Back to all trials